[1]Yang C, Wang H B, Zhao X J, et al. CKD in China: evolving spectrum and public health implications[J]. Am J Kidney Dis, 2020, 76(2): 258-264.
[2]Chen X J, Mao Y, Hu J B, et al. Perirenal fat thickness is significantly associated with the risk for development of chronic kidney disease in patients with diabetes[J]. Diabetes, 2021, 70(10): 2322-2332.
[3]Xue M, Fang T, Sun H, et al. PACS-2 attenuates diabetic kidney disease via the enhancement of mitochondria-associated endoplasmic reticulum membrane formation[J]. Cell Death Dis, 2021, 12(12): 1107.
[4]Thomas MC, Brownlee M, Susztak K, et al. Diabetic kidney disease[J]. Nat Rev Dis Primers, 2015, 1: 15018.
[5]Li H, Wei W, Xu H. Drug discovery is an eternal challenge for the biomedical sciences[J]. Acta Mater Med, 2022, 1(1): 1-3.
[6]Satirapoj B. Review on pathophysiology and treatment of diabetic kidney disease[J]. J Med Assoc Thai, 2010, 93(Suppl 6): S228-S241.
[7]Wu J, Sun Z, Yang S, et al. Kidney single-cell transcriptome profile reveals distinct response of proximal tubule cells to SGLT2i and ARB treatment in diabetic mice[J]. Mol Ther, 2022, 30(4): 1741-1753.
[8]Zhang L, Zhao M H, Zuo L, et al. China kidney disease network (CK-NET) 2016 annual data report[J]. Kidney Int Suppl (2011), 2020, 10(2): e97-e185.
[9]Mohan S, Reddick R L, Musi N, et al. Diabetic eNOS knockout mice develop distinct macro- and microvascular complications[J]. Lab Invest, 2008, 88(5): 515-528.
[10]Zhao M M, Lu J, Li S, et al. Berberine is an insulin secretagogue targeting the KCNH6 potassium channel[J]. Nat Commun, 2021, 12(1): 5616.
[11]Raz I, Wexler I, Weiss O. Role of insulin and the IGF system in renal hypertrophy in diabetic Psammomys obesus (sand rat)[J]. Nephrol Dial Transplant, 2003, 18(7): 1293-1298.
[12]Velasquez M T, Kimmel P L, Michaelis O E 4th. Animal models of spontaneous diabetic kidney disease[J]. FASEB J, 1990, 4(11): 2850-2859.
[13]Azushima K O, Gurley S B, Coffman T M. Modelling diabetic nephropathy in mice[J]. Nat Rev Nephrol, 2018, 14(1): 48-56.
[14]Ignarro L J, Byrns R E, Buga G M, et al. Endothelium-derived relaxing factor from pulmonary artery and vein possesses pharmacologic and chemical properties identical to those of nitric oxide radical[J]. Circ Res, 1987, 61(6): 866-879.
[15]Godo S, Sawada A, Saito H, et al. Disruption of physiological balance between nitric oxide and endothelium-dependent hyperpolarization impairs cardiovascular homeostasis in mice[J]. Arterioscler Thromb Vasc Biol, 2016, 36(1): 97-107.
[16]Reidy K, Kang H M, Hostetter T, et al. Molecular mechanisms of diabetic kidney disease[J]. J Clin Invest, 2014, 124(6): 2333-2340.
[17]Nakagawa T, Sato W, Kosugi T, et al. Uncoupling of VEGF with endothelial NO as a potential mechanism for abnormal angiogenesis in the diabetic nephropathy[J]. J Diabetes Res, 2013, 2013: 184539.
|